FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Hologic BioZorb Marker Recall Class 1: FDA

[ Price : $8.95]

FDA says a Hologic 3/2024 recall correction of BioZorb Markers was Class 1.

UCB Minzasolmin Parkinsons Study Misses Endpoints

[ Price : $8.95]

UCB says it is ending the development of minzasolmin, a drug it was working on with Novartis to treat early Parkinsons disease, af...

FDA Alert on Baxter Solution Sets

[ Price : $8.95]

FDA issues an alert against the use of certain Baxter Solution Sets with Duo-Vent Spikes because they were incorrectly assembled w...

FDA Promotes Centralized Statistical Trial Monitoring

[ Price : $8.95]

FDA encourages drug sponsors to use centralized statistical monitoring to help keep an eye on clinical trial integrity issues.

DTC Ad Enforcement to Increase Under Trump: Panel

[ Price : $8.95]

Lawyers on a Food & Drug Law Institute enforcement panel warn that the incoming Trump administration is likely to target and seek ...

FDA Sees New Ocaliva Liver Injuries

[ Price : $8.95]

FDA says it has identified serious liver injuries in patients without cirrhosis of the liver being treated for primary biliary cho...

FDA Hasnt Inspected Factory with Recalls: ProPublica

[ Price : $8.95]

A detailed ProPublica investigative report says FDA failed to inspect a Glenmark Pharmaceuticals facility in India that had multip...

Lykos to Appeal MDMA Drug Rejection

[ Price : $8.95]

After receiving a complete response letter, Lykos Therapeutics says it will pursue FDAs dispute resolution process to question the...

Loper Bright May End FDA Speech Ban: Attorney

[ Price : $8.95]

Reed Smith attorney James Beck says companies hit by FDA for off-label promotion may challenge the agencys reasoning under the new...

Syndax Leukemia Review Extended by FDA

[ Price : $8.95]

FDA extends by three months its review of a Syndax Pharmaceuticals NDA for revumenib and its use in treating adult and pediatric p...